02 8011 4217, 0416 974 651  info at scenar.com.au

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR MYOFASCIAL PAIN SYNDROME

INBOHAN,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

RYOONGHUH,MD

Department of Neurosurgery, Pochon CHA University, College of Medicine, 351, Yatap-dong, Bundang-Gu, Sungnam, 463-712, Korea

ABSTRACT

SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. We investigated the usefulness and effectiveness of SCENAR therapy in patients with MPS. SCENAR therapy was performed in 202 patients with MPS. The ratio of male to female was 1:4.5. The mean age was 47.3 years (range: 18-75 years). The mean follow up period was 6 months (range: 3 months-16months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy. The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory. This study suggests that SCENAR therapy would be very useful new method to deal with MPS.

INTRODUCTION

Myofascial pain syndrome (MPS) is a local or regional musculoskeletal pain disorder that may involve either a single muscle or a muscle group. It develops due to any number of causes including sudden trauma to musculoskeletal tissues. It seems to occur in virtually everyone’s lives at some point but becomes chronic and intractable in some cases. MPS has a significant impact on functional status, restricting occupational activities with marked socioeconomic repercussions. The management of MPS encompasses a range of different interventions, including trigger point injections, drug, exercise, patient education, physiotherapy, and alternative therapies. The treatment goals are to relieve pain, reduce muscle spasm, improve strength and range of motion, promote early return to activity, encourage active coping strategies, and ultimately improve functional status. The risks and benefits of these treatments vary. SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid 80s. We experienced the clinical benefit provided by SCENAR therapy and demonstrated the effectiveness of SCENAR therapy.

ISBN: 978-81-904262-8-2(RPS) ©2007 WACBE’07. All rights reserved.

METHODS

The study population was composed of 202 patients with MPS. The ratio of male to female was 1: 4.5. The mean age was 47.3 years (range: 18-75 years). SCENAR therapy was performed between August 2005 and December 2006. The mean frequency of this treatment was 3 times a week and the mean duration time per each treatment was 5 minutes. The mean follow up period was 6 months (range: 3 months- 16 months). The visual analogue scale (VAS) was used to assess the effectiveness of SCENAR therapy.

RESULTS

The overall improvement of pain was 89%. Especially, the improvement of acute pain was good, and all patients presenting MPS was satisfactory.

DISCUSSIONS

SCENAR was first invented in Russia in mid 80s under space and military research program. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body. Pain is the most common complaint to be dealt with in the SCENAR therapy by block of transmission of the pain impulses in the nerve endings of the peripheral nerve fibers, pain focus suppression of brain cortex, and reduction of the edema around the nerve fibers leading to reduction of pressure effect. SCENAR therapy is contraindicated in patients with cardiac pacemakers due to the potential of interfering with pacemaker activity.
SCENAR therapy can be differentiated from TENS. They use electrical stimulation. However, the pulse of the SCENAR device is bipolar and has short triangle and high amplitude. The electrodes of SCENAR device were fixed. Our study suggests that SCENAR therapy would be very useful method to deal with MPS.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pam in electrical nerve stimulation. Clinical
Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657-266

Proa of the 3rd WACBE World Congress on Bioengineering 2007

 

SCENAR THERAPY FOR LYMPHEDEMA

WACBE World Congress on Bioengineering 2007

Bangkok, THAILAND

SCENAR THERAPY FOR LYMPHEDEMA

R YOONG HUH, MD
Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu,Sungnam, 463-712, Korea
INBOHAN, MD Department of Neurosurgery, Pochon ???University, College of Medicine, 351, Yatap- dong, Bundang-Gu, SUngnam, 463-712, Korea

ABSTRACT
SCENAR standing for Self-Controlled Energo Neuro-Adaptive Regulator was first invented in mid 80s. The goal of therapy for Jymphedema is lymphatic drainage. We investigated the usefulness and effectiveness of SCENAR therapy in patients with lymphadema. SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in-7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment -was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment. The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, – SCENAR therapy would be very useful method to deal with lymphedema.

ISBN: 978-8l-904262-8-2(RPS) ©2007 WACBE’07. Ail rights reserved.

INTRODUCTION

Lymphedema is a debilitating progressive condition with no known cure. The underlying problem is lymphatic dysfunction, resulting in an abnormal accumulation of interstitial fluid containing hig h molecular weight proteins. It is usually observed following breast cancer surgery, particularly among those who undergo radiation therapy following axiallary lymphadenectomy. In a disease state, the lymphatic transport capacity is reduced. This causes the normal volume of interstitial fluid for mation to r\exceed the rate of lymphatic return, resulting in the stagnation of high molecular weigh t proteins in the interstitium. Surgical treatment is palliative, not curative, and it does not obviate the need for continued medical therapy.

SCENAR standing for Self Controlled Energo Neuro Adaptive Regulator was first invented in Russia in mid SOs. We experienced the clinical benefit provided by SCENAR therapy for patients with lymphedema and demonstrated the effectiveness of SCENAR therapy.

METHODS

SCENAR therapy was performed in 28 patients with lymphadema. All patients were female and were performed radiation treatment due to breast cancer in 7 patients, cervical cancer in 13 patients, and ovarian cancer in 8 patients. The mean age was 53.7 years (range: 37-65 years). The mean frequency of SCENAR therapy was 4 times a week and the mean duration time per each treatment was 8 minutes. The mean follow up period was 7 months (range: 3 months-18months). The circumference of affected extremities was measured before and after treatment.

RESULTS
The overall improvement of lymphadema was 79% and the pain associated with lymphadema also improved in 85 % of patients.

DISCUSSIONS
Lymphedema is a notoriously debilitating progressive condition caused by damage or removal of regional lymph nodes through surgery, radiation, infection, or tumor invasion. The goal of therapy is lymphatic drainage. SCENAR device generates electrical impulses that are physiologically similar to neuroimpulses. In respond to a SCENAR impulse, reflex biofeedback proceeds at real time and biological speed. By continuously using biofeedback, the SCENAR modifies each successive input signal to either amplify or dampen the form of the pathological signals that exist in the body.
Although the pathophysiology of lymphedema is still unclear, it has been reported that protein and fluid accumulation initiates a marked inflammatory reaction in the interstitium. Macrophage activity is increased, resulting in destruction of elastic fibers and production of fibrosclerotic tissue.
The result of this inflammatory reaction is a change from the initial edema to the brawny nonpitting edema characteristics of lymphedema. This study suggested that the SCENAR device impulse helps fluid come out of the lymphatic system and improves the microcirculation. SCENAR device also eliminates inflammatory process in the lymph nodes. Therefore, SCENAR therapy would be very useful method to deal with lymphedema.

REFERENCES
[1] Verhoeven, K., Dijk, J.V. Decreasing pain in electrical nerve stimulation. Clinical Neurophysiology., 7/7(2006),972-978.
[2] Khadilkar, A., Milne, S., Brosseau, L., Wells, G, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systemic review. Spine., 30 (2005), 2657- 266

Proc. of the 3rd WACBE World Congress on Bioengineering 2007